Overview of the autoimmune disease diagnostics market
The autoimmune disease diagnostics market is anticipated to grow at a steady state and will post a CAGR of more than 6% over the forecast period. The discovery of novel biomarkers is one of the major factors propelling the growth prospects of this market. With the development of novel biomarkers, there has been a significant improvement in the diagnosis of autoimmune diseases. The use of singular conventional biomarkers proves to be of little help as individuals with autoimmune diseases can develop multiple symptoms that can be difficult for the physicians to diagnose. Therefore, there is an increased demand for multiple biomarkers that could help identify and evaluate the patient status, disease type, and progression and response to therapy for autoimmune diseases. Moreover, the development of autoantibodies to a given protein is witnessed only in a few people with autoimmune disorders. This has led researchers to conduct extensive R&D activities that are showing positive results in the use of multiple biomarkers for the diagnosis of autoimmune diseases. The ability to screen an individual with multiple biomarkers associated with several autoimmune diseases has improved the disease diagnosis considerably.
In terms of geography, the Americas led the global autoimmune disease diagnostics market and will continue to dominate the market in the coming years. The growing incidence of autoimmune disorders such as RA, SLE, and IBD will aid in the growth of this market. Also, the extensive R&D activities has allowed the launch of novel diagnostic products, which
Outlook of the immunohematology market
Extensive research carried out by the analysts at Technavio has shown that the global immunohematology market will witness steady growth and will post a moderate CAGR of close to 5% over the forecast period. The growing demand for blood banks across the globe is one of the primary factors propelling the growth prospects of this market. Most blood banks collect blood from donors using bloodmobile or the donor visits a designated center for blood donation. After collection of the blood, it undergoes several rounds of immunohematology tests such as screening for infectious diseases and blood typing and serological tests for blood plasma, after which it is sent to hospitals and healthcare centers for transfusion. Moreover, cord blood banking is becoming increasingly popular as cord blood contain stem cells, which is the safest option to treat genetic disorders. After collection of cord blood, the blood bank preserves it after conducting immunohematology tests, leading to this market’s growth in the future.
A paradigm shift toward molecular immunohematology is one of the recent trends gaining significant traction in the market. Molecular analysis helps in detection of the molecular and genetic basis of any antigen. This method helps healthcare providers to understand the molecular basis of blood group antigen and blood typing. Before blood transfusion from unrelated donor registries, this method has become a gold standard method to understand the cross-matching of donor and recipient blood. Moreover, most
Overview of the global dermatology diagnostic devices market
Market research analysts at Technavio predict that the global dermatology diagnostic devices market will grow steadily and post a CAGR of around 9% by 2020. One of the key drivers for this market will be the increasing demand for advanced dermatology diagnostic services. The introduction of dermatoscopy to diagnose skin conditions will simplify the diagnostic approach and enable ease of use for physicians. Additionally, factors like advancements in technology, especially in the field of dermatology diagnostic devices will also enhance the accuracy and sensitivity of detection mechanisms. Technological innovation promotes the use of digital dermatoscopy for the early detection of non-malignant melanomas and the subsequent increase in the number of mobile-based technologies for diagnosis of conditions will also help patients in tracking and monitoring moles over a regular period of time.
The recent trend in the market is the growing importance of dermatology in the cosmetic industry. Dermatology procedures emphasize on the diagnosis, prevention, and treatment of skin-related diseases and involves the diagnosis and treatment of conditions such as benign skin growth, uneven skin pigmentation, fungal or bacterial infections, acne, and aging. Furthermore, the emergence of digital dermatoscopy to examine and diagnose skin disorders and the extensive use of OCT scanners will also help in the deep dermal analysis of skin tissues, making diagnosis more precise and specific.
Competitive landscape and key vendors
This market is extremely competitive and appears fragmented due to the presence of various regional and international players. The vendors compete on the basis of the cost of equipment, access to devices, and accuracy of diagnosis
Overview of the global clinical reference laboratory services market
According to the market research analyst at Technavio, the global clinical reference laboratory services market will grow progressively at a modest CAGR of approximately 6% by 2020. One of the major factors attributing to the growth of the market will be the usage of advanced robotics technology in reference laboratories as they increase productivity, elevate experimental data quality, and reduce lab process cycle times. Additionally, the application of laboratory automation technology will improve the efficiency and effectiveness of the diagnostics and testing process. With the help of this technology, laboratories will be able to perform critical activities such as thorough screening, combination chemistry, automated clinical and analytical testing, and large-scale biorepositories. It has been observed that there are expansions of new fully automated instruments such as immunostainer platforms in anatomic pathology or DNA extractors in molecular diagnostics with reduced processing time and low operating costs. Also, these devices help reference laboratories to handle the movement of specimens across disciplines, giving faster results to meet the turnaround time for clients.
The research analyst predicts that the Americas will dominate the market and post a CAGR of around 6% by 2020. The increasing focus on early detection and prevention of diseases, innovations of molecular and genetic technologies, and the revolution of personalized medicines are few of the factors that will contribute the growth of the market during the forecast period. The rising numbers of FDA approvals for new diagnostics procedures will result in vendors focusing on the launch of new, time-saving, and cost-effective diagnostics procedures to increase their market shares.
Competitive landscape and key vendors
It has been observed
Overview of the point-of-care (POC) coagulation testing market
Extensive research carried out by the analysts at Technavio has shown that the global point-of-care (POC) coagulation testing market will grow at a fast pace and will post a CAGR of more than 6% over the forecast period. The increasing penetration of POCT devices in developed countries is one of the significant factors driving the growth of this market. Moreover, the reimbursement system in most European countries like Spain and the UK has led to an augmented demand for diagnostic equipment, especially POCT devices. Additionally, the majority of POCT device manufacturers in developed countries are increasingly focussing on design to provide the latest in technology for quick and accurate diagnosis. This will enable healthcare providers to take the necessary precautions while conducting major surgeries. Also, the new-age POC coagulation testing devices are portable and easy to use, leading to their increased adoption in hospitals and clinics in the US and Western Europe.
In terms of geography, the Americas led the global POC coagulation testing market and is expected to hold close to 67% of the revenue market shares by 2020. The US was the largest revenue contributor in this region. The increase in pulmonary embolisms, stroke, and myocardial infarction caused by blood clotting disorders in the population is driving the market. Also, improved clinical diagnostic procedures and favorable initiatives by the WHO for the development of novel products is also anticipated to contribute to this market’s growth in the region.
Competitive landscape and key vendors
Outlook of the global hepatitis B and C diagnostics market
The analyst at Technavio, predicts that the global hepatitis B and C diagnostics market will grow steadily and post a moderate CAGR of approximately 6% by 2020. The rising demand for molecular diagnostic of HBV (hepatitis B virus) and HCV (hepatitis C virus) infections is one of the primary drivers for the growth of this market. Molecular diagnosis simplifies sample preparation for high-volume testing and includes identification and profiling of causative agents of infection and the quantification of pathogens to monitor durability of therapy; thus, resulting in sales of around 60% of the overall molecular diagnosis market. Additionally, new companies are also focusing on the development of new products, which, in turn, is expected to change market dynamics for the diagnosis of HBV and HCV infections. For instance, Cepheid recently announced a quantitative test that offers on-demand molecular testing for confirmation of infection and monitoring of HCV and has obtained CE-IVD (in vitro diagnostics) status under the European Directive on in-vitro diagnostic medical devices, making it one of the leading platforms for molecular diagnosis.
Increasing incidence of HBV and HCV infections in the Americas will contribute to the growth of the diagnostic market. According to the analyst at Technavio, the Americas will dominate the market, accounting for around 46% of the total market share by 2020. The recent increase in blood transfusion will result in the adoption of third-generation hepatitis C diagnostic tests like HCV enzyme immunoassay that contribute to the growth of the market in this region. Also, the implementation of biomarker-based POC (point-of-care) tests initiated by the government and non-profit organizations, is also expected to drive the market growth as the products are highly accessible and easy to use.
Competitive landscape and
In-vitro diagnostics is one of the fastest-growing sectors in healthcare. Cost-containment strategies by healthcare entities have led to an increased focus on early diagnosis, preventive medicine, and personalized medicine.
This move towards preventive and personalized medicine is driving the adoption of in-vitro diagnostics, and vendors are focusing on developing tests for a wide range of applications for hospitals and laboratories, as well as for home care. The presence of a high number of market participants has significantly intensified competition.